Quchang Ouyang

Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial

Binghe Xu, Min Yan, Fei Ma et al. · The Lancet Oncology · 2021 · 393 citations

Medicine, Oncology, Pharmacology +16

Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study

Fei Ma, Quchang Ouyang, Wěi Li et al. · Journal of Clinical Oncology · 2019 · 345 citations

Medicine, Oncology, Pharmacology +17

Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial

Binghe Xu, Qingyuan Zhang, Pin Zhang et al. · Nature Medicine · 2021 · 169 citations

Medicine, Oncology, Pharmacology +12

Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Pin Zhang, Qingyuan Zhang, Zhongsheng Tong et al. · The Lancet Oncology · 2023 · 95 citations

Medicine, Oncology, Pharmacology +16

Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial

Peng Yuan, Xichun Hu, Tao Sun et al. · European Journal of Cancer · 2019 · 88 citations

Medicine, Oncology, Pharmacology +11